Century Therapeutics
IPSC
About: Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
6% less funds holding
Funds holding: 70 [Q1] → 66 (-4) [Q2]
8.1% less ownership
Funds ownership: 34.36% [Q1] → 26.26% (-8.1%) [Q2]
10% less capital invested
Capital invested by funds: $14.1M [Q1] → $12.6M (-$1.43M) [Q2]
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
Financial journalist opinion
